131^I治疗分化型甲状腺癌淋巴结转移的疗效及影响因素分析
被引量：1
摘要
淋巴结转移是分化型甲状腺癌（DTC）最主要的转移途径。本研究回顾性分析了131^I治疗DTC淋巴结转移的疗效及其影响因素，现报道如下.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2009年第2期102-102,共1页
Chinese Journal of Nuclear Medicine
参考文献2
-
1Lin JD, Chen ST, Hsueh C, et al. A 29-year retrospective review of papillary thyroid cancer in one institution. Thyroid, 2007, 17 : 535- 541. 被引量：1
-
2Woodrum DT, Guager PG. Role of 131I in the treatment of well differentiated thyroid cancer.J Surg Oncol, 2005, 89: 114-121. 被引量：1
同被引文献14
-
1Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline ( version 1.1 ) [ J ]. Eur J Cancer, 2009, 45 ( 2 ) :228-247. 被引量：1
-
2Hay ID, Bergstralh EJ, Goellner JR, et al. Predieting outeome in papillary thyroid carcinoma: developmen! of a reliable prognostic scoring system in a eohort of 1779 patients surgically treated at one institution during 1940 through 1989 [J]. Surgery, 1993, 114 (6) :1050-1058. 被引量：1
-
3NCCN Guidelines Version I. 2013 thyroid eaieinoma [ EB/OL]. http//www, neen. org/professionals/physieian_ gls/pdf/thyroid. pdf. 被引量：1
-
4Cooper DS, Doherty GM, Haugen BR, el al. Revised American Thyroid Association manangement guidelines for patients with thyrnid nodules and differentiated thyroid cancer. The American Thyroid Association ATA guidelines taskforce on thyrnid nodules and differentiated thyroid cancer[ J]. Thyroid, 2009, 19 ( 11 ) : 1167-1214. 被引量：1
-
5Woodrum DT, Guager PG. Role of 131I in the treatment of well differentiated thyroid cancer [ J ]. J Surg Oncol, 2005, 89 ( 3 ) : 114-121. 被引量：1
-
6YimJH, Kim WB, Kim EY, et al. The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation. J Clin Endocrinol Metab, 2011, 96 (7) :2049-2056. 被引量：1
-
7Uruno T, Miyauchi A, Shimizu K, et al. Prognosis after reoperation for local recurrence of papillary thyroid carcinoma [ J ]. Surg Today, 2004, 34 ( 11 ) :891-895. 被引量：1
-
8Schuff KG, Weber SM, Givi B, et al. Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer [ J ]. Laryngoscope, 2008, 118 (5) :768-775. 被引量：1
-
9Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma[J]. Thyroid, 1997, 7(2) :265-271. 被引量：1
-
10Sehvartz C, Bonnetain F, Dabakuyo S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients [ J ]. J Clin Endocrinol Metab, 2012, 97 (5) : 1526-1535. 被引量：1
二级引证文献5
-
1张敬伟,段冬梅,袁小笋,张蕾,任中海.碘联合优甲乐治疗对甲状腺乳头状癌术后细胞转移及患者生存率的影响[J].中国地方病防治,2017,32(3):278-280. 被引量：1
-
2张玉华,王宇,张峰,吕谦.甲状腺乳头状癌不同治疗方式的疗效探讨[J].中国医药指南,2018,16(3):80-81. 被引量：1
-
3康乐平,李俊川.多灶性甲状腺癌患者的手术疗效及预后影响因素[J].海南医学,2018,29(9):1221-1224. 被引量：8
-
4王伟.甲状腺全切除术联合同位素和激素治疗乳头状甲状腺癌的疗效分析[J].医药前沿,2018,8(25):9-11.
-
5舒卉.硒酵母胶囊联合左甲状腺素钠片治疗对甲状腺乳头状癌术后转移及生存时间的影响[J].临床合理用药杂志,2024,17(25):105-107.
-
1朱博.分化型甲状腺癌术后^(131)I治疗的护理体会[J].中国现代药物应用,2014,8(13):209-210. 被引量：2
-
2余云云,李雨升,郑飞波,刘建滨.大剂量^(131)I治疗36例分化型甲状腺癌转移灶的临床分析[J].放射免疫学杂志,2004,17(4):247-249. 被引量：3
-
3崔邦平,代文莉,胡涛,严凯,胡伟.甲状腺乳头状癌NIS蛋白表达对^(131)I疗效的预测及与BRAF基因突变的关系[J].现代肿瘤医学,2013,21(4):746-748. 被引量：4
-
4冯方,王辉,付宏亮,李佳宁,叶智轶,杜学亮,吴靖川.分化型甲状腺癌细胞株^(131)I照射后摄碘能力及特异基因表达变化的实验研究[J].放射免疫学杂志,2009,22(2):97-100. 被引量：5
-
5吴真,杜学亮,吴靖川,冯国强,谷蓉,吴斌.血清HTgRIA对分化型甲状腺癌^(131)I治疗后随访的评价[J].放射免疫学杂志,2004,17(4):301-301. 被引量：2
-
6于苏国,孙吉花.^(131)I治疗Graves病的疗效及安全性[J].山东医药,2009,49(17):106-107. 被引量：2
-
7薛胜利,吴德沛,李金利,张日,邵景章,陈子兴.^(131)I治疗甲状腺功能亢进后并发白血病1例[J].临床血液学杂志,2005,18(6):375-375.
-
8刘媛媛,潘明志.^(131)I治疗分化型甲状腺癌肺转移疗效及影响因素的研究[J].同济大学学报（医学版）,2012,33(3):58-63. 被引量：14
-
9潘晓梅,段东,朱玉泉,庞华.分化型甲状腺癌首次大剂量131^I治疗后99^Tc^m-MIBI显像的价值[J].中华核医学与分子影像杂志,2015,35(5):383-386. 被引量：3
-
10郭恒照,朱亚平,毛延涛,王传玺,房奇,韩俊庆,丛林,李强.碘[^(131)I]美妥昔单抗注射液与肝动脉化疗栓塞术治疗原发性肝癌的对比研究[J].成都医学院学报,2015,10(6):649-651. 被引量：2
